Compare HOFT & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOFT | IMUX |
|---|---|---|
| Founded | 1924 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.6M | 152.6M |
| IPO Year | 1999 | 2013 |
| Metric | HOFT | IMUX |
|---|---|---|
| Price | $13.30 | $0.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 30.4K | ★ 2.6M |
| Earning Date | 04-16-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.68% | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $278,139,000.00 | N/A |
| Revenue This Year | $17.37 | N/A |
| Revenue Next Year | $9.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.46 | $0.51 |
| 52 Week High | $15.99 | $1.51 |
| Indicator | HOFT | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 47.37 | 35.61 |
| Support Level | $9.27 | $0.78 |
| Resistance Level | $13.47 | $0.88 |
| Average True Range (ATR) | 0.98 | 0.10 |
| MACD | -0.13 | -0.04 |
| Stochastic Oscillator | 26.43 | 3.99 |
Hooker Furnishings Corp is a designer, marketer and importer of casegoods (wooden and metal furniture), leather furniture, fabric-upholstered furniture, lighting, accessories, and home decor for the residential, hospitality and contract markets. It is also domestically manufactured premium residential custom leather, custom fabric-upholstered furniture, and outdoor furniture. The company operates in four segment Hooker Branded segment, Home Meridian segment, Domestic Upholstery segment and All Other.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.